Sensitivity analyses of the primary efficacy endpoint in a randomized-withdrawal phase 3 trial of tapentadol extended release (ER) in patients with painful diabetic peripheral neuropathy (DPN)

Authors :: Juergen Haeussler
D.Y. Shapiro
A. Steup
Mila Etropolski
Akiko Okamoto
Source :: Canadian Journal of Diabetes. 33:244-245
Publication Year :: 2009
Publisher :: Elsevier BV, 2009.

Subjects :: business.industry
Endocrinology, Diabetes and Metabolism
General Medicine
medicine.disease
Tapentadol
Endocrinology
Peripheral neuropathy
Anesthesia
Internal Medicine
Medicine
In patient
Extended release
business
Sensitivity analyses
medicine.drug

Full Text Access

Tools